EU approval for self-administered Crysvita
Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
Read More
Tag: XLH
Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population
New approval includes older adolescents and adults with rare disease
Read More
CHMP backs expanding scope of Kyowa Kirin’s Crysvita
The decision could see older adolescents and adults access the treatment for X-linked hypophosphataemia (XLH)
Read More
XLH patients to get routine access to first new therapy in 30 years
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
Read More
NICE u-turn approves funding for rare disease therapy Crysvita
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.
Read More
Rare disease therapy Crysvita to be barred from NHS
Children and young people with X-linked hypophosphataemia (XLH) are unlikely to get routine access to Kyowa Kirin’s Crysvita on the NHS.
Read More
FDA clears first therapy for inherited rickets
US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
